The North America Anti-Hepatitis C Drugs report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and o
Notes: *indicates p<.05; **p<.01; ***p<.001; Standard errors in parentheses. Based on the 342 new molecular entities (with at least one patent) approved by the U.S. Food and Drug Administration betwee
Background: Several studies have resulted in controversial data about the recurrence or new incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C who were treated with direct-acting
